![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety Profile of HIV-1 Attachment Inhibitor Prodrug
BMS-663068 in Antiretroviral-Experienced Subjects:
Week 24 Analysis
|
|
|
Reported by Jules Levin
HIV Glasgow 2014,
2-6 November 2014, Glasgow, UK
J Lalezari1, GH Latiff2, C Brinson3, J Echevarría4, S Treviño-Pérez5, JR Bogner6, D Stock7, SR Joshi7, GJ Hanna8, M Lataillade7, for the AI438011 study team
1Quest Clinical Research, San Francisco, CA, USA; 2Maxwell Clinic, Durban, South Africa; 3Central Texas Clinical Research, Austin, TX, USA;
4Hospital Nacional Cayetano Heredia, Lima, Peru; 5Mexico Centre for Clinical Research, Mexico City, Mexico; 6Hospital of the University of Munich, Munich, Germany;
7Bristol-Myers Squibb, Wallingford, CT, USA; 8Bristol-Myers Squibb, Princeton, NJ, USA
![AASLD1.gif](../images/111214/111214-17/AASLD1.gif)
![AASLD2.gif](../images/111214/111214-17/AASLD2.gif)
![AASLD3.gif](../images/111214/111214-17/AASLD3.gif)
![AASLD4.gif](../images/111214/111214-17/AASLD4.gif)
![AASLD5.gif](../images/111214/111214-17/AASLD5.gif)
![AASLD6.gif](../images/111214/111214-17/AASLD6.gif)
![AASLD7.gif](../images/111214/111214-17/AASLD7.gif)
![AASLD8.gif](../images/111214/111214-17/AASLD8.gif)
![AASLD9.gif](../images/111214/111214-17/AASLD9.gif)
![AASLD10.gif](../images/111214/111214-17/AASLD10.gif)
![AASLD11.gif](../images/111214/111214-17/AASLD11.gif)
![AASLD12.gif](../images/111214/111214-17/AASLD12.gif)
![AASLD13.gif](../images/111214/111214-17/AASLD13.gif)
![AASLD14.gif](../images/111214/111214-17/AASLD14.gif)
![AASLD15.gif](../images/111214/111214-17/AASLD15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|